Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Broker's call: Shriram Transport Finance

2018-07-09 thehindubusinessline
In our May 2018 reinitiating coverage note on Shriram Transport Finance (SHTF), we had indicated that 1) we expect per cent16 per cent 3-year AUM CAGR of SHTF as the estimated financing opportunity for 5-10 year pre-owned vehicles is ₹2.5 lakh crore, ii) With NPA recognition at 90+ DPD, pace of fresh NPA creation will moderate leading to improvement in FY19E credit cost; and 3) margins can come under pressure if SHTF targets lower vintage vehicles.
511218 500470 TTST TATASTEEL TATLY SRRQY SRTRANSFIN

0
Shriram group mulls merger of Shriram Transport Finance, City Union

2018-07-09 livemint
New Delhi:Non-banking financial firms Shriram Transport Finance Company and Shriram City Union Finance (SCUF) are in early stages of discussion for merger, a person privy of the matter said on Monday.
511218 532498 SHRIRAMCIT SRRQY SRTRANSFIN

0
Shriram Transport Finance shares move up 4%

2018-07-05 thehindubusinessline
Shares of Shriram Transport Finance Co Ltd rose as much as 4.3 per cent to Rs 1,194.35, their biggest intraday percentage gain since April 5. The group firm SVL Ltd has the wherewithal to honour repayment on non-convertible debentures (NCDs) guaranteed by it, STFC said on Wednesday
511218 536507 DB SRRQY SRTRANSFIN FLFL

0
Shriram Transport Finance stock up 9% post-clarification on SVL loan matter

2018-07-05 moneycontrol
Shriram Transport Finance Corporation share price rebounded 9 percent after the company's clarification note on SVL loan soothed investors' sentiment. The stock had fallen 12 percent in previous session as investors had turned cautious of a guarantee of Rs 870 crore provided by the firm for its unlisted subsidiary.
511218 SRRQY SRTRANSFIN

0
Group co has enough resources to repay dues: Shriram Transport

2018-07-04 freepressjournal.in
Mumbai : Shriram Transport Finance on Wednesday said that its promoters are in talks with SVL Group to ensure that the latter makes payment of dues to the company on or before the stipulated date.
511218 SRRQY SRTRANSFIN

0
Shriram Transport shares plunge on worries over subsidiary’s NCDs

2018-07-04 thehindubusinessline
The share price of Shriram Transport Finance Corporation (STFC) witnessed its sharpest fall in 19 months on Wednesday as global research firm Jefferies said one of the company’s unlisted subsidiary, SVL Ltd, may have inadequate cash flows to service debt raised via non convertible debentures (NCDs).
511218 SHRIRAMEPC MS.PRI MS.PRK SRRQY MS.PRE MS.PRF MS.PRG 532945 MS MS.PRA SRTRANSFIN

0
Shriram Transport Finance says group firm will honour NCD repayment

2018-07-04 livemint
Bengaluru: Shriram Transport Finance Co Ltd (STFC) said on Wednesday group firm SVL Ltd has the wherewithal to honour repayment on non-convertible debentures (NCDs) guaranteed by it.
511218 SHRIRAMEPC MS.PRI MS.PRK SRRQY MS.PRE MS.PRF MS.PRG 532945 MS MS.PRA SRTRANSFIN

5
An evening walk down Dalal Street: MSP price hike gives a push to Indian markets; Sensex rallies over 250 points

2018-07-04 moneycontrol
The S&P BSE Sensex rallied over 200 points on Wednesday despite negative global cues. The Nifty50 reclaimed 10,700 levels and closed above its short-term moving averages such as 5-EMA, 13-EMA, as well as 50-EMA which is a bullish sign.
UNICHEMLAB KOHINOOR 539275 532899 BHRQY SRTRANSFIN 511218 532454 512559 532783 506690 KSCL SRRQY MSL 500570 BHARTIARTL TATAMOTORS DAAWAT TTM

1
Closing Bell: Banks, RIL lift Sensex 267 pts; Nifty ends above 10,750 despite weak Asia

2018-07-04 moneycontrol
Global Update: Asian markets ended in the red with China's Shanghai Composite losing a percent after recording gains in the previous session. Trade tensions remained in the spotlight ahead of a looming tariff deadline, reports CNBC.
BAJAJ-AUTO KOHINOOR MUTHOOTFIN BHRYY 500325 UBL RELIANCE 532978 532977 533398 SRTRANSFIN 532478 511218 532783 532187 532121 506690 534816 RIGD SRRQY HDFCBANK BJJQY INFRATEL RLNIY 500034 UNICHEMLAB INDUSINDBK UBHOLDINGS 539126 UNBWY MEP 512559 BAJAJFINSV BAJFINANCE HDB 500180 DENABANK 507458 DAAWAT

0
Movers shakers: Volumes of Indiabulls Ventures, Shriram Transport rose the most in last 5 days

2018-07-04 moneycontrol
The market was on an uptrend this Wednesday afternoon with the Nifty up 70 points at 10,770 and the Sensex gaining 262 points at 35,641.
GRASIM GRSJY GRAPHITE IBVENTURES 532967 SRTRANSFIN KIRIINDUS IDBLZ 511218 532960 GRSXY SRRQY 500300 509488

0
Market Live: Nifty at day#39;s high, Sensex up over 250 pts; Bajaj Auto, Bharti Infratel top gainers

2018-07-04 moneycontrol
Buzzing: Unichem Laboratories share price rallied more than 5 percent intraday after the company received final ANDA approval for its Montelukast Chewable tablets, 4 mg and 5 mg from the United States Food and Drug Administration to market in the US.
BAJAJ-AUTO KOHINOOR BHRYY 500325 UBL RELIANCE 532978 532977 SRTRANSFIN 532478 511218 532783 532121 506690 534816 RIGD SRRQY BJJQY INFRATEL RLNIY 500034 UNICHEMLAB UBHOLDINGS UNBWY 512559 506022 BAJAJFINSV BAJFINANCE PRAKASH DENABANK 507458 DAAWAT

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

10h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

11h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...